---
title: "Wuhan Hiteck Biological Pharma Co., Ltd. (300683.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300683.SZ.md"
symbol: "300683.SZ"
name: "Wuhan Hiteck Biological Pharma Co., Ltd."
industry: "Biotechnology"
datetime: "2026-05-20T10:00:01.876Z"
locales:
  - [en](https://longbridge.com/en/quote/300683.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300683.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300683.SZ.md)
---

# Wuhan Hiteck Biological Pharma Co., Ltd. (300683.SZ)

## Company Overview

Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Epramine for injection; mouse nerve growth factor for injection; Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pectoris, myocardial infarction, myocarditis, and cardiogenic shock; aciclovir dispersible tablets for the treatment of genital herpes virus infection, herpes zoster, and immune deficiency chickenpox; Pentoxone theobromine injection; Roxatidine Acetate Hydrochloride for Injection; and Terizazole phosphate for injection. The company also provides measles and rubella virus nucleic acid detection kits; isolation and identification tubes and kits for mycoplasma; and bacterial vaginosis (BV) rapid test kits, as well as diagnostic kits for novel coronavirus N-Protein. In addition, it offers diagnostic kits for IgG antibody to measles virus, hydatid, toxoplasma, rubella virus, cytomegalo virus, and herpes simplex virus I/II; diagnostic kits for IgM antibody to measles virus, herpes simplex virus I/II, cytomegalo virus, rubella virus, and toxoplasma; and diagnostic kits for a –Thalassemia.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.hiteck.com.cn](https://www.hiteck.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: D (0.65)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 75 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -19.28% |  |
| Net Profit YoY | -260.21% |  |
| P/B Ratio | 2.16 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4618300462.11 |  |
| Revenue | 544792295.51 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -10.65% | D |
| Profit Margin | -44.20% | E |
| Gross Margin | 38.47% | B |
| Revenue YoY | -19.28% | E |
| Net Profit YoY | -260.21% | E |
| Total Assets YoY | -9.80% | E |
| Net Assets YoY | -10.49% | D |
| Cash Flow Margin | 12.17% | D |
| OCF YoY | -19.28% | E |
| Turnover | 0.20 | D |
| Gearing Ratio | 15.68% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Wuhan Hiteck Biological Pharma Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-19.28%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-260.21%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.16",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4618300462.11",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "544792295.51",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-10.65%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-44.20%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "38.47%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-19.28%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-260.21%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-9.80%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-10.49%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "12.17%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-19.28%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.20",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "15.68%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -19.18 | 56/81 | - | - | - |
| PB | 2.16 | 27/81 | 2.24 | 1.91 | 1.65 |
| PS (TTM) | 8.48 | 40/81 | 8.50 | 6.94 | 5.93 |
| Dividend Yield | 0.00% | - | 0.47% | 0.40% | 0.31% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300683.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300683.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300683.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300683.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**